1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

With TheraFlu PowerPods, GSK Brews Market For OTCs From Coffee Makers

 
• By Eileen Francis

GSK takes Theraflu brand from medicine cabinet to kitchen with launch of PowerPods of OTC ingredients delivered through single-serve coffee makers. Introduction of non-coffee pods also is growing, including lemonade, hot ciders, teas and Campbell's Soup pods.

GlaxoSmithKline PLC is inviting consumers to use an OTC cough/cold remedy where they cook by offering TheraFlu PowerPods, pods of ingredients used with single-serve coffee makers.

GSK is the first OTC brand manufacturer to launch a formulation in a single-serve pod, though US drugstore chain CVS Health Corp. has offered generic TheraFlu formulations in pods...

TheraFlu PowerPods contain OTC monograph ingredients and “no additional FDA approval was needed” to offer the formulation in the new delivery format, said Latisha Tillie, GSK's Theraflu senior brand manager....

More from United States

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 
• By Sarah Karlin-Smith

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

More from North America